CD62P and P10 as Predictive Markers for Assessing the Efficacy of Hemodialysis in Treating End-Stage Renal Disease

Journal of Clinical Laboratory Analysis - United States
doi 10.1002/jcla.22662
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Effect of Teaching Guidelines on Self-Efficacy for Patients With End Stage Renal Disease Undergoing Hemodialysis

Port Said Scientific Journal of Nursing
2017English

Restless Legs Syndrome in End-Stage Renal Disease Patients Undergoing Hemodialysis

Arquivos de Neuro-Psiquiatria
Biological PsychiatryNeurology
2018English

Efficacy of Different Hemodialysis Methods on Dendritic Cell Marker CD40 and CD80 and Platelet Activation Marker CD62P and P10 in Patients With Chronic Renal Failure

Journal of Clinical Laboratory Analysis
AllergyImmunologyBiochemistryPublic HealthMedical Laboratory TechnologyClinical BiochemistryHematologyMicrobiologyEnvironmentalOccupational Health
2018English

A Comparison Between Urea Reduction Ratio and Urea Kinetic Model in Assessing Hemodialysis Adequacy in End Stage Renal Disease

International Journal of Clinical Biochemistry and Research
2018English

Sudden Death in End Stage Renal Disease: Comparing Hemodialysis Versus Peritoneal Dialysis

Blood Purification
MedicineHematologyNephrology
2017English

Similar Outcomes With Hemodialysis and Peritoneal Dialysis in Patients With End-Stage Renal Disease

Archives of Internal Medicine
2011English

Increased Sympathetic Renal Innervation in Hemodialysis Patients Is the Anatomical Substrate of Sympathetic Hyperactivity in End‐Stage Renal Disease

Journal of the American Heart Association
Cardiovascular MedicineCardiology
2015English

Comparison of Peritoneal Dialysis and Hemodialysis as First Renal Replacement Therapy in Patients With End-Stage Renal Disease and Diabetes: A Systematic Review

Renal Replacement Therapy
2019English

Risk Factors for End-Stage Renal Disease

Archives of Internal Medicine
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy